MCID: ADR005
MIFTS: 62

Adrenal Carcinoma

Categories: Cancer diseases, Endocrine diseases, Nephrological diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Adrenal Carcinoma

MalaCards integrated aliases for Adrenal Carcinoma:

Name: Adrenal Carcinoma 12 36 6 15
Adrenal Cancer 12 74 20 54 71
Adrenal Gland Cancer 12 42 15
Malignant Neoplasm of Adrenal Gland 12 32
Adrenal Gland Neoplasms 44 71
Carcinoma of the Adrenal Gland 12
Tumor of the Adrenal Gland 12
Neoplasm of Adrenal Gland 12
Adrenocortical Carcinoma 71
Malignant Adrenal Tumor 12
Adrenal Gland Neoplasm 17
Adrenal Neoplasm 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3950 DOID:3953
KEGG 36 H00033
ICD9CM 34 194.0
MeSH 44 D000310
NCIt 50 C2859 C9338
SNOMED-CT 67 127021009 93665005
ICD10 32 C74 C74.9
UMLS 71 C0001624 C0206686 C0750887

Summaries for Adrenal Carcinoma

GARD : 20 Adrenal cancer is a rare form of cancer that occurs due to abnormal and uncontrolled cell growth in the adrenal glands (small glands that sit above each kidney). There are three different types of adrenal cancer which vary by location and the age at which they are often diagnosed: Adrenocortical carcinoma - The most common type of adrenal cancer which develops in the adrenal cortex (the outer part of the adrenal gland) Neuroblastoma - A childhood cancer that begins in the adrenal medulla (the inner part of the adrenal gland) Pheochromocytoma - A neuroendocrine tumor that begins in the adrenal medulla The signs and symptoms associated with the condition largely depend on if the cancer is 'functioning' (producing hormones) or 'nonfunctioning' (not producing hormones) and which hormones are present in excess. In most cases, the underlying cause of the condition is unknown. However, certain genetic conditions such as multiple endocrine neoplasia type 2, Li-Fraumeni syndrome, Von Hippel-Lindau syndrome, neurofibromatosis type I, and Carney complex are associated with an increased risk of developing adrenal tumors and cancer. Treatment may include a combination of surgery, hormone therapy, chemotherapy and radiation therapy.

MalaCards based summary : Adrenal Carcinoma, also known as adrenal cancer, is related to small cell carcinoma and gangliocytoma, and has symptoms including fever and flank pain. An important gene associated with Adrenal Carcinoma is TP53 (Tumor Protein P53), and among its related pathways/superpathways are Toll-like Receptor Signaling Pathway and G-Beta Gamma Signaling. The drugs Etomidate and Lenograstim have been mentioned in the context of this disorder. Affiliated tissues include adrenal glands which are located above the kidneys, adrenal gland and thyroid, and related phenotypes are Reduced mammosphere formation and behavior/neurological

Disease Ontology : 12 An endocrine gland cancer located in the adrenal glands which are located above the kidneys.

MedlinePlus : 42 Your adrenal, or suprarenal, glands are located on the top of each kidney. These glands produce hormones that you can't live without, including sex hormones and cortisol, which helps you respond to stress and has many other functions. A number of disorders can affect the adrenal glands, including tumors. Tumors can be either benign or malignant. Benign tumors aren't cancer. Malignant ones are. Most adrenal gland tumors are benign. They usually do not cause symptoms and may not require treatment. Malignant adrenal gland cancers are uncommon. Types of tumors include Adrenocortical carcinoma - cancer in the outer part of the gland Neuroblastoma, a type of childhood cancer Pheochromocytoma - a rare tumor that is usually benign Symptoms depend on the type of cancer you have. Treatments may include surgery, chemotherapy, or radiation therapy.

KEGG : 36 Adrenocortical carcinoma (ACC) is a rare endocrine malignancy defined by a heterogeneous clinical presentation, dismal prognosis, and lack of effective therapeutic regimens. The incidence of ACC ranges from 0.5 to 2 cases per million people per year, accounting for 0.02% of all reported cancers. Unfortunately, most patients present with metastatic disease which reduces the 5 year survival rate to less than 10%. Oncogenes and tumor-suppressor genes involved in adrenal carcinomas include mutations in the p53 tumor-suppressor gene and rearrangements of the chromosomal locus 11p15.5 associated with IGF II hyperexpression. Deletions of the ACTH receptor gene have recently been found in undifferentiated adenomas and in aggressive ACCs.

Wikipedia : 74 An adrenal tumor or adrenal mass is any benign or malignant neoplasms of the adrenal gland, several of... more...

Related Diseases for Adrenal Carcinoma

Diseases related to Adrenal Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 405)
# Related Disease Score Top Affiliating Genes
1 small cell carcinoma 31.0 TP53 SYP ENO2
2 gangliocytoma 31.0 SYP POMC ENO2 CRH
3 lymphangioma 31.0 TP53 PIK3CA CTNNB1 CCND1
4 neuroblastoma 30.6 TP53 SYP PIK3CA NRAS IGF2 ENO2
5 hypokalemia 30.6 POMC CYP17A1 CRH
6 adrenogenital syndrome 30.6 SYP CYP21A2
7 conn's syndrome 30.5 POMC GNAS CYP21A2 CYP17A1 CYP11B2 CRH
8 amenorrhea 30.5 POMC CYP17A1 CRH
9 thyroid gland follicular carcinoma 30.4 TP53 PIK3CA NRAS CTNNB1 CCND1 BRAF
10 lipoid congenital adrenal hyperplasia 30.3 POMC CYP21A2 CYP17A1 CYP11B2
11 pheochromocytoma 30.3 SYP POMC IGF2 ENO2 CRH CCND1
12 malignant pheochromocytoma 30.2 SYP MIR483 ENO2
13 renal cell carcinoma, nonpapillary 30.2 TP53 PIK3CA NRAS ENO2 CCND1 BRAF
14 hypoaldosteronism 30.2 POMC CYP11B2
15 adrenal cortical carcinoma 30.2 TP53 SYP POMC PIK3CA NRAS MIR483
16 penile cancer 30.2 TP53 PIK3CA CCND1
17 liposarcoma 30.1 TP53 PIK3CA CTNNB1 CCND1
18 multiple endocrine neoplasia, type i 30.1 SYP POMC MIR483 GNAS
19 adrenal cortical adenoma 30.0 SYP POMC MIR483 IGF2 ENO2 CYP21A2
20 beckwith-wiedemann syndrome 30.0 TP53 MIR483 IGF2 GNAS CTNNB1
21 adenoma 29.9 TP53 SYP POMC PIK3CA GNAS CYP21A2
22 adrenal adenoma 29.9 POMC MIR483 IGF2 GNAS CYP21A2 CYP17A1
23 adrenal neuroblastoma 11.1
24 adrenal medulla cancer 11.1
25 adenomatoid tumor 10.6
26 malignant melanocytic neoplasm of the peripheral nerve sheath 10.5 SYP ENO2
27 anal neuroendocrine tumor 10.5 SYP ENO2
28 esophageal leukoplakia 10.5 TP53 CCND1
29 optic nerve astrocytoma 10.5 SYP ENO2
30 cerebral neuroblastoma 10.5 SYP ENO2
31 neuronal intestinal dysplasia, type b 10.5 SYP ENO2
32 lung meningioma 10.5 SYP ENO2
33 sinonasal undifferentiated carcinoma 10.5 SYP ENO2
34 auditory system benign neoplasm 10.5 SYP ENO2
35 desmoplastic infantile ganglioglioma 10.5 SYP BRAF
36 small cell carcinoma of the bladder 10.5 SYP ENO2
37 auditory system cancer 10.5 SYP ENO2
38 cloacogenic carcinoma 10.5 SYP ENO2
39 pineal region teratoma 10.5 SYP ENO2
40 extraosseous ewings sarcoma-primitive neuroepithelial tumor 10.5 SYP ENO2
41 cauda equina neoplasm 10.5 SYP ENO2
42 autoimmune hepatitis type 2 10.5 CYP21A2 CYP17A1
43 intracranial primitive neuroectodermal tumor 10.5 SYP ENO2
44 pancreatic foamy gland adenocarcinoma 10.5 TP53 CCND1
45 vulvar intraepithelial neoplasia 10.5 TP53 CTNNB1
46 nodular prostate 10.5 SYP ENO2
47 ampulla of vater neoplasm 10.5 SYP ENO2
48 bile duct mucinous adenocarcinoma 10.5 TP53 SYP ENO2
49 appendix carcinoid tumor 10.5 SYP ENO2
50 frontal lobe neoplasm 10.5 TP53 SYP ENO2

Graphical network of the top 20 diseases related to Adrenal Carcinoma:



Diseases related to Adrenal Carcinoma

Symptoms & Phenotypes for Adrenal Carcinoma

UMLS symptoms related to Adrenal Carcinoma:


fever, flank pain

GenomeRNAi Phenotypes related to Adrenal Carcinoma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Reduced mammosphere formation GR00396-S 9.17 BRAF CCND1 CYP21A2 GNAS IGF2 NRAS

MGI Mouse Phenotypes related to Adrenal Carcinoma:

46 (show all 21)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.49 BRAF CCNB1 CCND1 CRH CTNNB1 CYP17A1
2 growth/size/body region MP:0005378 10.45 BRAF CCND1 CRH CTNNB1 CYP11B2 CYP17A1
3 cellular MP:0005384 10.39 BRAF CCND1 CRH CTNNB1 CYP17A1 ENO2
4 homeostasis/metabolism MP:0005376 10.37 BRAF CCND1 CRH CTNNB1 CYP11B2 CYP17A1
5 cardiovascular system MP:0005385 10.32 BRAF CCND1 CTNNB1 CYP11B2 CYP17A1 GNAS
6 immune system MP:0005387 10.32 BRAF CCND1 CRH CTNNB1 CYP11B2 CYP21A2
7 hematopoietic system MP:0005397 10.31 BRAF CCND1 CRH CTNNB1 CYP11B2 CYP21A2
8 endocrine/exocrine gland MP:0005379 10.3 BRAF CCND1 CRH CTNNB1 CYP11B2 GNAS
9 mortality/aging MP:0010768 10.28 BRAF CCNB1 CCND1 CTNNB1 CYP17A1 CYP21A2
10 integument MP:0010771 10.27 BRAF CCND1 CRH CTNNB1 CYP21A2 GNAS
11 adipose tissue MP:0005375 10.2 BRAF CRH CYP11B2 CYP17A1 GNAS PIK3CA
12 nervous system MP:0003631 10.18 BRAF CCND1 CRH CTNNB1 CYP11B2 ENO2
13 craniofacial MP:0005382 10.17 BRAF CCND1 CTNNB1 ENO2 GNAS IGF2
14 liver/biliary system MP:0005370 10.16 BRAF CRH CTNNB1 CYP11B2 GNAS GRN
15 limbs/digits/tail MP:0005371 10.02 BRAF CRH CTNNB1 GNAS IGF2 NRAS
16 neoplasm MP:0002006 10.01 BRAF CCND1 CTNNB1 GNAS NRAS PIK3CA
17 no phenotypic analysis MP:0003012 9.97 CRH CTNNB1 GNAS GRN IGF2 NRAS
18 renal/urinary system MP:0005367 9.85 BRAF CCNB1 CRH CTNNB1 CYP11B2 GNAS
19 pigmentation MP:0001186 9.73 BRAF CTNNB1 GRN NRAS POMC TP53
20 respiratory system MP:0005388 9.56 BRAF CCND1 CRH CTNNB1 ENO2 GNAS
21 skeleton MP:0005390 9.36 BRAF CCND1 CRH CTNNB1 CYP17A1 GNAS

Drugs & Therapeutics for Adrenal Carcinoma

Drugs for Adrenal Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 133)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Etomidate Approved Phase 3 33125-97-2 36339 667484
2
Lenograstim Approved, Investigational Phase 3 135968-09-1
3
Iodine Approved, Investigational Phase 3 7553-56-2 807
4
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
5
Streptozocin Approved, Investigational Phase 3 18883-66-4 29327
6
Mitotane Approved Phase 3 53-19-0 4211
7
Cisplatin Approved Phase 3 15663-27-1 84093 441203 2767
8
Etoposide Approved Phase 3 33419-42-0 36462
9
Cadexomer iodine Experimental Phase 3 94820-09-4
10 Hypnotics and Sedatives Phase 3
11 Anesthetics Phase 3
12 Anesthetics, General Phase 3
13 Anesthetics, Intravenous Phase 3
14 Antibiotics, Antitubercular Phase 3
15
Liposomal doxorubicin Phase 3 31703
16 Anti-Bacterial Agents Phase 3
17 Insulin, Globin Zinc Phase 3
18 Mitogens Phase 3
19 insulin Phase 3
20 Antimitotic Agents Phase 3
21 Tubulin Modulators Phase 3
22 Antineoplastic Agents, Hormonal Phase 3
23 Etoposide phosphate Phase 3
24 Keratolytic Agents Phase 3
25 Dermatologic Agents Phase 3
26 Podophyllotoxin Phase 3 518-28-5
27
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
28
Docetaxel Approved, Investigational Phase 2 114977-28-5 148124
29
Sunitinib Approved, Investigational Phase 2 341031-54-7, 557795-19-4 5329102
30
Gefitinib Approved, Investigational Phase 2 184475-35-2 123631
31
Sodium citrate Approved, Investigational Phase 2 68-04-2
32
Tamoxifen Approved Phase 2 10540-29-1 2733526
33
Lactitol Approved, Investigational Phase 2 585-86-4 157355
34
acetic acid Approved Phase 2 64-19-7 176
35
Vincristine Approved, Investigational Phase 2 2068-78-2, 57-22-7 5978
36
Axitinib Approved, Investigational Phase 2 319460-85-0 6450551
37
Oxaliplatin Approved, Investigational Phase 2 61825-94-3 5310940 9887054 6857599 43805
38
Ipilimumab Approved Phase 2 477202-00-9
39
Pembrolizumab Approved Phase 2 1374853-91-4
40
nivolumab Approved Phase 2 946414-94-4
41
Hydrocortisone acetate Approved, Vet_approved Phase 2 50-03-3
42
Hydrocortisone Approved, Vet_approved Phase 2 50-23-7 5754
43
Vitamin A Approved, Nutraceutical, Vet_approved Phase 2 68-26-8, 11103-57-4 445354
44
Tyrosine Approved, Investigational, Nutraceutical Phase 2 60-18-4 6057
45
Citric acid Approved, Nutraceutical, Vet_approved Phase 2 77-92-9 311
46 Gossypol Investigational Phase 2 303-45-7
47
Suramin Investigational Phase 2 145-63-1 5361
48 Adrenocorticotropic Hormone Phase 2
49 Liver Extracts Phase 2
50 Retinol palmitate Phase 2

Interventional clinical trials:

(show top 50) (show all 102)
# Name Status NCT ID Phase Drugs
1 Randomized Clinical Trial of Posterior Retroperitoneoscopic Adrenalectomy Versus Lateral Transperitoneal Laparoscopic Adrenalectomy With a Five-year Follow-up Completed NCT01959711 Phase 4
2 Combined 18F-Fluorodeoxyglucose (FDG) Positron Emission Tomography (PET) and 123I-Iodometomidate (123I-IMTO) Imaging for Adrenal Neoplasia Unknown status NCT02010957 Phase 3
3 Efficacy of Adjuvant Mitotane Treatment in Prolonging Recurrence-free Survival in Patients With Adrenocortical Carcinoma at Low-intermediate Risk of Recurrence Unknown status NCT00777244 Phase 3 MITOTANE
4 Treatment of Adrenocortical Tumors With Surgery Plus Lymph Node Dissection and Multiagent Chemotherapy: A Groupwide Phase III Study Unknown status NCT00304070 Phase 3 doxorubicin hydrochloride;cisplatin;mitotane;etoposide
5 Changes in Adrenal Hormones During Adrenal Radiofrequency Ablation Completed NCT00997594 Phase 2, Phase 3
6 Iodine I-131 Iodocholesterol, Its Use in Adrenal Screening Completed NCT00037843 Phase 3 I-131 Iodocholesterol
7 A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of OSI-906 in Patients With Locally Advanced or Metastatic Adrenocortical Carcinoma Completed NCT00924989 Phase 3 OSI-906
8 First International Randomized Trial in Locally Advanced and Metastatic Adrenocortical Carcinoma Treatment Completed NCT00094497 Phase 3 Etoposide;Doxorubicin;Cisplatin;Streptozotocin;Mitotane
9 Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Participants With Stage I-III Adrenocortical Cancer With High Risk of Recurrence Recruiting NCT03723941 Phase 3 Cisplatin plus Etoposide
10 Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Participants With Stage I-III Adrenocortical Cancer With High Risk of Recurrence (ADIUVO-2) Recruiting NCT03583710 Phase 3 Cisplatin;Etoposide;Mitotane
11 Sorafenib Plus Paclitaxel Metronomic Chemotherapy in Adreno-Cortical-Carcinoma Patients Progressing After 1st or 2nd Line Cytotoxic Chemotherapy Unknown status NCT00786110 Phase 2 Sorafenib;Paclitaxel
12 A Phase II, Open-label, Dose Titration, Multi-center Study to Assess the Safety/Tolerability and Efficacy of Osilodrostat in Patients With All Types of Endogenous Cushing's Syndrome Except Cushing's Disease Completed NCT02468193 Phase 2 Osilodrostat
13 Evaluation of 123I-Iodometomidate for Adrenal Scintigraphy Completed NCT00454103 Phase 1, Phase 2 123I-Iodometomidate
14 Phase II Trial With Taxotere and Cisplatin in Non-operable Adrenocortical Carcinoma Completed NCT00324012 Phase 2 cisplatin, taxotere
15 Phase II Trial of Surgical Resection and Heated Intraperitoneal Peritoneal Chemotherapy (HIPEC) for Adrenocortical Carcinoma Completed NCT01833832 Phase 2 Cisplatin;sodium thiosulfate
16 Sunitinib in Refractory Adrenocortical-Carcinoma Patients Progressing After Cytotoxic Chemotherapy Completed NCT00453895 Phase 2 Sunitinib
17 A Phase II Trial of ZD1839 (Iressa) in Patients With Nonresectable Adrenocortical Carcinoma (ACC) Completed NCT00215202 Phase 2 Iressa (ZD1839)
18 Cisplatin, Doxorubicin and Tamoxifen in the Treatment of Incurable Soft Tissue and Endocrine Malignancies Completed NCT00002608 Phase 2 cisplatin;doxorubicin hydrochloride;tamoxifen citrate
19 Phase II Clinical Trial of Dovitinib (TKI-258) in First-line Metastatic or Locally Advanced Non-resectable Adrenocortical Carcinoma Completed NCT01514526 Phase 2 Dovitinib
20 A Phase II Study of the Orally Administered Negative Enantiomer of Gossypol (AT-101) in Patients With Advanced Adrenocortical Carcinoma (ACC) Completed NCT00848016 Phase 2 R-(-)-gossypol acetic acid
21 A Study of Combination Chemotherapy and Surgical Resection in the Treatment of Adrenocortical Carcinoma: Continuous Infusion Doxorubicin, Vincristine and Etoposide With Daily Mitotane Before and After Surgical Resection Completed NCT00001339 Phase 2 doxorubicin, vincristine, and etoposide with mitotane
22 A Phase 1/2 Dose Escalation Study to Determine the Safety, Pharmacokinetics, and Pharmacodynamics of Intravenous TKM-080301 in Patients With Advanced Solid Tumors Completed NCT01262235 Phase 1, Phase 2 TKM-080301
23 Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-Pathway in Metastatic, Recurrent or Primary Unresectable Adrenocortical Cancer Completed NCT01255137 Phase 2 Axitinib
24 A Study of Combination Chemotherapy & Surgical Resection in the Tx of Adrenocortical Cancer: Mitotane & Continuous Infusion Doxorubicin, Vincristine & Etoposide w/the P-glycoprotein Antagonist, Tariquidar (XR9576), Before & After Surgical Resection Completed NCT00071058 Phase 2 XR9576 (Tariquidar)
25 A Phase II Study of Oxaliplatin in Children With Recurrent Solid Tumors Completed NCT00091182 Phase 2 oxaliplatin
26 A Phase II Study of IMC-A12 (Anti-IGF-I Receptor Monoclonal Antibody, NSC #742460) in Children With Relapsed/Refractory Solid Tumors Completed NCT00831844 Phase 2
27 Phase II Study to Evaluate the Effects of Cabozantinib in Patients With Unresectable/Metastatic Adrenocortical Carcinoma Recruiting NCT03612232 Phase 2 Cabozantinib-s-malate
28 A Phase 1/2 Trial of a Novel Therapeutic Vaccine (EO2401) in Combination With Immune Check Point Blockade, for Treatment of Patients With Locally Advanced or Metastatic Adrenocortical Carcinoma, or Malignant Pheochromocytoma/Paraganglioma Recruiting NCT04187404 Phase 1, Phase 2
29 Phase II Trial of Surgical Resection and Heated Intraperitoneal Peritoneal Chemotherapy (HIPEC) for Adrenocortical Carcinoma Recruiting NCT03127774 Phase 2 Cisplatin;Sodium thiosulfate
30 Multicenter, Prospective, Non-randomized, Phase II Trial Designed to Evaluate the Activity of Cabazitaxel in Patients With Advanced Adreno-Cortical- Carcinoma Progressing After Previous Chemotherapy Lines Recruiting NCT03257891 Phase 2 Cabazitaxel
31 A Phase II Study to Evaluate the Effects of Cabozantinib in Patients With Unresectable/Metastatic Adrenocortical Carcinoma Recruiting NCT03370718 Phase 2 Cabozantinib
32 Phase II Study for the Evaluation of Efficacy of Pembrolizumab (MK-3475) in Patients With Rare Tumors Recruiting NCT02721732 Phase 2
33 DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors Recruiting NCT02834013 Phase 2
34 A Phase II Study of Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors Recruiting NCT03333616 Phase 2 Ipilimumab;Nivolumab
35 A Phase II Clinical Trial of Single Agent Pembrolizumab in Subjects With Advanced Adrenocortical Carcinoma Active, not recruiting NCT02673333 Phase 2 Pembrolizumab
36 Activity of Abiraterone Acetate in the Management of Cushing's Syndrome in Patients With Adrenocortical Carcinoma Active, not recruiting NCT03145285 Phase 2 Abiraterone Acetate
37 Phase 2 Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults With Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors Active, not recruiting NCT02867592 Phase 2 Cabozantinib;Cabozantinib S-malate
38 Phase II Study for Combination of Camrelizumab and Apatinib in the Second-line Treatment of Recurrent or Metastatic Adrenocortical Carcinoma Not yet recruiting NCT04318730 Phase 2 Camrelizumab
39 Phase II Study of Antineoplastons A10 and AS2-1 In Patients With Carcinoma of the Adrenal Gland Terminated NCT00003453 Phase 2 Antineoplaston therapy (Atengenal + Astugenal)
40 Randomized Control Trial of Adrenalectomy Versus Observation for Subclinical Hypercortisolism Terminated NCT02001051 Phase 2
41 Evaluation of Suramin in Advanced Adrenal Cortical Carcinoma, Phase II Terminated NCT00002921 Phase 2 suramin;therapeutic hydrocortisone
42 Multi-Institutional Phase II Study of IMC-A12, a Recombinant Human IgG1 Monoclonal Antibody Directed at the Type I Insulin-Like Growth Factor Receptor IGF1R, in Adrenocortical Carcinoma: IMC-A12 With Mitotane vs Mitotane Alone Terminated NCT00778817 Phase 2 mitotane
43 Phase II Study of Nivolumab (Anti-PD-1 Antibody) for Treatment of Metastatic Adrenocortical Carcinoma Terminated NCT02720484 Phase 2 Nivolumab
44 A Phase II Study of Bevacizumab in Patients With Nonresectable Cancer of the Adrenal Cortex. Withdrawn NCT00469469 Phase 2 Bevacizumab
45 Phase 1 Study of the Safety and Tolerability of ATR-101 in Adrenocortical Carcinoma Completed NCT01898715 Phase 1 ATR-101
46 A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of Avelumab (MSB0010718C) in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications Completed NCT01772004 Phase 1 Avelumab
47 Adrenal Scans With Radioiodine-Labeled Norcholesterol (NP-59) Completed NCT00591643 Phase 1
48 A Phase I Trial of Suramin With Sequential Doxorubicin in Patients With Advanced Solid Tumors Completed NCT00003038 Phase 1 doxorubicin hydrochloride;suramin
49 A Phase 1 Dose Escalation Study of Seneca Valley Virus (NTX-010), A Replication-Competent Picornavirus, in Relapsed/Refractory Pediatric Patients With Neuroblastoma, Rhabdomyosarcoma, or Rare Tumors With Neuroendocrine Features Completed NCT01048892 Phase 1 cyclophosphamide
50 A Phase I Trial of Herceptin and Interleukin-12 Completed NCT00004074 Phase 1

Search NIH Clinical Center for Adrenal Carcinoma

Cochrane evidence based reviews: adrenal gland neoplasms

Genetic Tests for Adrenal Carcinoma

Anatomical Context for Adrenal Carcinoma

The Foundational Model of Anatomy Ontology organs/tissues related to Adrenal Carcinoma:

19
Adrenal Glands Which Are Located Above The Kidneys

MalaCards organs/tissues related to Adrenal Carcinoma:

40
Adrenal Gland, Thyroid, Cortex, Adrenal Cortex, Lymph Node, Bone, Liver

Publications for Adrenal Carcinoma

Articles related to Adrenal Carcinoma:

(show top 50) (show all 869)
# Title Authors PMID Year
1
ENSAT registry-based randomized clinical trials for adrenocortical carcinoma. 42
33166271 2021
2
Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. 42
32861807 2020
3
Imaging of Adrenal-Related Endocrine Disorders. 42
33040851 2020
4
The modification and expression of 21-hydroxylase gene in normal human adrenal gland and adrenal cancer. 61 54
1687042 1991
5
Suspicious adrenal incidentaloma in a patient with Congenital Adrenal Hyperplasia: A case report. 61
33511036 2021
6
β-catenin in adrenal zonation and disease. 61
33338548 2021
7
[A Case of Adrenal Anastomosing Hemangioma]. 61
33535290 2021
8
Delaying Cancer Cases in Urology during COVID-19: Review of the Literature. 61
32692934 2020
9
[French ccAFU guidelines - update 2020-2022: malignancy assessment of an adrenal incidentaloma]. 61
33349429 2020
10
Laparoscopic Right Adrenalectomy in a Large Right Adrenal Oncocytic Carcinoma. 61
33244737 2020
11
Disseminated nocardiosis with adrenal abscess masquerading as metastatic adrenal cancer in an immunocompetent adult. 61
33137243 2020
12
Robotic and Laparoscopic Approaches for Adrenal Surgery in Obese Patients. 61
33131284 2020
13
Development of an index of complexity for outpatient endocrinology and nutrition clinics. 61
32507700 2020
14
Uncommon tumors in multiple endocrine neoplasia (MEN) type 1: Do they have a relationship with the prognosis of these patients? 61
32909176 2020
15
[The no-need-to-see process for adrenal incidentalomas]. 61
33000724 2020
16
Etomidate infusion at low doses is an effective and safe treatment for severe Cushing's syndrome outside intensive care. 61
32449698 2020
17
The Functional Role of Long Non-coding RNA UCA1 in Human Multiple Cancers: a Review Study. 61
32560605 2020
18
CaseReport: Aldosterone-secreting adrenal carcinoma complicating longstanding hypertension. 61
31089198 2020
19
Adrenal angiosarcoma with metastasis: Imaging and histopathology of a rare adrenal cancer. 61
32123554 2020
20
Bilateral adrenal histoplasmosis presenting as adrenal insufficiency in an immunocompetent host in the Philippines. 61
32404324 2020
21
Two giant retroperitoneal schwannomas mimicking adrenal malignancy - a case report. 61
33506097 2020
22
Three-year follow up of adrenal incidentalomas in a New Zealand centre. 61
31058434 2020
23
A Man with a Clot on his Platelets: Adrenal Carcinoma and Dynamic Right Ventricular Inflow Obstruction. 61
31442387 2020
24
Are Adrenal Lesions of 6 cm or More in Diameter a Contraindication to Laparoscopic Adrenalectomy? A Case-Control Study. 61
31728629 2020
25
From ACTH-Dependent to ACTH-Independent Cushing's Syndrome from a Malignant Mixed Corticomedullary Adrenal Tumor: Potential Role of Embryonic Stem Cells. 61
32426170 2020
26
Smoking is associated with adrenal adenomas and adrenocortical carcinomas: a nationwide multicenter analysis. 61
32871402 2020
27
Adropin Stimulates Proliferation and Inhibits Adrenocortical Steroidogenesis in the Human Adrenal Carcinoma (HAC15) Cell Line. 61
33133015 2020
28
[An Uncommon Cause of Arterial Hypertension]. 61
32456579 2020
29
Nomograms for the Prediction of Survival for Patients with Pediatric Adrenal Cancer after Surgery. 61
32127935 2020
30
Adrenal tumours: open surgery versus minimally invasive surgery. 61
31644473 2020
31
Primary extragonadal yolk sac tumor originating from adrenal gland. 61
31860425 2019
32
Successful treatment of metastatic adrenocortical carcinoma in the spine: A case report and literature review. 61
31804360 2019
33
Fairly rare small-diameter hepatocellular carcinoma with right adrenal gland metastasis having an inferior vena cava tumor thrombus: a case report. 61
31696344 2019
34
Antineoplastic Effect of a Combined Mitotane Treatment/Ionizing Radiation in Adrenocortical Carcinoma: A Preclinical Study. 61
31717612 2019
35
Changes in total and acylated ghrelin levels during mitotane treatment in patients with adrenocortical carcinoma. 61
31169262 2019
36
Impact of Three-dimensional Printing in Urology: State of the Art and Future Perspectives. A Systematic Review by ESUT-YAUWP Group. 61
31109814 2019
37
Review and Comparison of Computational Approaches for Joint Longitudinal and Time-to-Event Models. 61
32042217 2019
38
Right atrial and ventricular invasion by adrenal carcinoma: A case report. 61
31440309 2019
39
Natural History of Adrenal Incidentalomas With and Without Mild Autonomous Cortisol Excess: A Systematic Review and Meta-analysis. 61
31234202 2019
40
[A Case of WDHA Water Diarrhea Hypokalemia Achlorhydria Syndrome that Developed after Multimodal Therapy for Retroperitoneal Paraganglioma]. 61
31501391 2019
41
Erythrocytosis as the first manifestation of adrenal carcinoma. 61
30859743 2019
42
Metastatic Carcinomas of the Adrenal Glands: From Diagnosis to Treatment. 61
31177104 2019
43
Adrenal tumors: when to search for a germline abnormality? 61
30985498 2019
44
[Adrenal carcinoma with vena cava thrombus]. 61
30758566 2019
45
Diagnostic value of PET textural indices for malignancy of FDG-avid adrenal lesions. 61
30916534 2019
46
Evaluating the effectiveness of computed tomography-guided 125I seed interstitial implantation in patients with secondary adrenal carcinoma. 61
31436236 2019
47
ADRENAL CARCINOMA IN CHILDREN: LONGITUDINAL STUDY IN MINAS GERAIS, BRAZIL. 61
30066822 2019
48
Hypertensive choroidopathy and adrenal carcinoma: A new association. 61
30337095 2019
49
Treatment and management of adrenal cancer in a specialized Australian endocrine surgical unit: approaches, outcomes and lessons learnt. 61
30710432 2019
50
[A CASE REPORT: A PATIENT WITH METASTATIC ADRENOCORTICAL CARCINOMA EXCLUSIVELY TREATED WITH MITOTANE WITH LONG-TERM FOLLOW-UP]. 61
31956212 2019

Variations for Adrenal Carcinoma

ClinVar genetic disease variations for Adrenal Carcinoma:

6 (show top 50) (show all 67)
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 TP53 NM_000546.5(TP53):c.470T>C (p.Val157Ala) SNV Likely pathogenic 428887 rs1131691023 17:7578460-7578460 17:7675142-7675142
2 TP53 NM_000546.5(TP53):c.638G>T (p.Arg213Leu) SNV Likely pathogenic 376650 rs587778720 17:7578211-7578211 17:7674893-7674893
3 CTNNB1 NM_001904.4(CTNNB1):c.134C>G (p.Ser45Cys) SNV Likely pathogenic 376242 rs121913409 3:41266137-41266137 3:41224646-41224646
4 CTNNB1 NM_001904.4(CTNNB1):c.133T>C (p.Ser45Pro) SNV Likely pathogenic 17589 rs121913407 3:41266136-41266136 3:41224645-41224645
5 TP53 NM_000546.5(TP53):c.700T>A (p.Tyr234Asn) SNV Likely pathogenic 376692 rs864622237 17:7577581-7577581 17:7674263-7674263
6 NRAS NM_002524.5(NRAS):c.182A>C (p.Gln61Pro) SNV Likely pathogenic 280409 rs11554290 1:115256529-115256529 1:114713908-114713908
7 TP53 NM_000546.5(TP53):c.818G>C (p.Arg273Pro) SNV Likely pathogenic 231060 rs28934576 17:7577120-7577120 17:7673802-7673802
8 TP53 NM_000546.5(TP53):c.518T>A (p.Val173Glu) SNV Likely pathogenic 376669 rs1057519747 17:7578412-7578412 17:7675094-7675094
9 TP53 NM_000546.5(TP53):c.518T>C (p.Val173Ala) SNV Likely pathogenic 376017 rs1057519747 17:7578412-7578412 17:7675094-7675094
10 BRAF NM_004333.6(BRAF):c.1780G>C (p.Asp594His) SNV Likely pathogenic 375947 rs397516896 7:140453155-140453155 7:140753355-140753355
11 CTNNB1 NM_001904.4(CTNNB1):c.121A>G (p.Thr41Ala) SNV Likely pathogenic 17580 rs121913412 3:41266124-41266124 3:41224633-41224633
12 TP53 NM_000546.5(TP53):c.374C>A (p.Thr125Lys) SNV Likely pathogenic 216465 rs786201057 17:7579313-7579313 17:7675995-7675995
13 CTNNB1 NM_001904.4(CTNNB1):c.122C>A (p.Thr41Asn) SNV Likely pathogenic 376394 rs121913413 3:41266125-41266125 3:41224634-41224634
14 TP53 NM_000546.5(TP53):c.824G>C (p.Cys275Ser) SNV Likely pathogenic 376583 rs863224451 17:7577114-7577114 17:7673796-7673796
15 TP53 NM_000546.5(TP53):c.404G>A (p.Cys135Tyr) SNV Likely pathogenic 141762 rs587781991 17:7578526-7578526 17:7675208-7675208
16 TP53 NM_000546.5(TP53):c.518T>G (p.Val173Gly) SNV Likely pathogenic 376016 rs1057519747 17:7578412-7578412 17:7675094-7675094
17 TP53 NM_000546.5(TP53):c.404G>T (p.Cys135Phe) SNV Likely pathogenic 376559 rs587781991 17:7578526-7578526 17:7675208-7675208
18 TP53 NM_001276697.2(TP53):c.-75T>C SNV Likely pathogenic 376560 rs1057519975 17:7578527-7578527 17:7675209-7675209
19 TP53 NM_000546.5(TP53):c.818G>T (p.Arg273Leu) SNV Likely pathogenic 376655 rs28934576 17:7577120-7577120 17:7673802-7673802
20 NRAS NM_002524.5(NRAS):c.183A>T (p.Gln61His) SNV Likely pathogenic 373003 rs121913255 1:115256528-115256528 1:114713907-114713907
21 TP53 NM_000546.5(TP53):c.374C>T (p.Thr125Met) SNV Likely pathogenic 183748 rs786201057 17:7579313-7579313 17:7675995-7675995
22 TP53 NM_000546.5(TP53):c.637C>G (p.Arg213Gly) SNV Likely pathogenic 376651 rs397516436 17:7578212-7578212 17:7674894-7674894
23 CTNNB1 NM_001904.4(CTNNB1):c.101G>T (p.Gly34Val) SNV Likely pathogenic 17582 rs28931589 3:41266104-41266104 3:41224613-41224613
24 TP53 NM_000546.5(TP53):c.405C>G (p.Cys135Trp) SNV Likely pathogenic 376561 rs1057519976 17:7578525-7578525 17:7675207-7675207
25 CTNNB1 NM_001904.4(CTNNB1):c.101G>C (p.Gly34Ala) SNV Likely pathogenic 376390 rs28931589 3:41266104-41266104 3:41224613-41224613
26 TP53 NM_000546.5(TP53):c.403T>A (p.Cys135Ser) SNV Likely pathogenic 376562 rs1057519975 17:7578527-7578527 17:7675209-7675209
27 NRAS NM_002524.5(NRAS):c.181C>A (p.Gln61Lys) SNV Likely pathogenic 73058 rs121913254 1:115256530-115256530 1:114713909-114713909
28 TP53 NM_000546.5(TP53):c.403T>G (p.Cys135Gly) SNV Likely pathogenic 376563 rs1057519975 17:7578527-7578527 17:7675209-7675209
29 CTNNB1 NM_001904.4(CTNNB1):c.101G>A (p.Gly34Glu) SNV Likely pathogenic 17584 rs28931589 3:41266104-41266104 3:41224613-41224613
30 TP53 NM_000546.5(TP53):c.701A>C (p.Tyr234Ser) SNV Likely pathogenic 376690 rs587780073 17:7577580-7577580 17:7674262-7674262
31 BRAF NM_001374258.1(BRAF):c.1901A>G (p.Asp634Gly) SNV Likely pathogenic 13972 rs121913338 7:140453154-140453154 7:140753354-140753354
32 TP53 NM_000546.5(TP53):c.638G>C (p.Arg213Pro) SNV Likely pathogenic 231214 rs587778720 17:7578211-7578211 17:7674893-7674893
33 CTNNB1 NM_001904.4(CTNNB1):c.134C>A (p.Ser45Tyr) SNV Likely pathogenic 375895 rs121913409 3:41266137-41266137 3:41224646-41224646
34 TP53 NM_000546.5(TP53):c.817C>A (p.Arg273Ser) SNV Likely pathogenic 376656 rs121913343 17:7577121-7577121 17:7673803-7673803
35 TP53 NM_000546.5(TP53):c.700T>G (p.Tyr234Asp) SNV Likely pathogenic 219759 rs864622237 17:7577581-7577581 17:7674263-7674263
36 TP53 NM_000546.5(TP53):c.701A>G (p.Tyr234Cys) SNV Likely pathogenic 127820 rs587780073 17:7577580-7577580 17:7674262-7674262
37 TP53 NM_000546.5(TP53):c.374C>G (p.Thr125Arg) SNV Likely pathogenic 376667 rs786201057 17:7579313-7579313 17:7675995-7675995
38 CTNNB1 NM_001904.4(CTNNB1):c.100G>C (p.Gly34Arg) SNV Likely pathogenic 376233 rs121913399 3:41266103-41266103 3:41224612-41224612
39 TP53 NM_000546.5(TP53):c.373A>C (p.Thr125Pro) SNV Likely pathogenic 376666 rs1057520003 17:7579314-7579314 17:7675996-7675996
40 TP53 NM_000546.5(TP53):c.823T>C (p.Cys275Arg) SNV Likely pathogenic 376584 rs1057519983 17:7577115-7577115 17:7673797-7673797
41 TP53 NM_000546.5(TP53):c.824G>T (p.Cys275Phe) SNV Likely pathogenic 376582 rs863224451 17:7577114-7577114 17:7673796-7673796
42 CTNNB1 NM_001904.4(CTNNB1):c.134C>T (p.Ser45Phe) SNV Likely pathogenic 17588 rs121913409 3:41266137-41266137 3:41224646-41224646
43 CTNNB1 NM_001904.4(CTNNB1):c.122C>T (p.Thr41Ile) SNV Likely pathogenic 17587 rs121913413 3:41266125-41266125 3:41224634-41224634
44 TP53 NM_000546.5(TP53):c.824G>A (p.Cys275Tyr) SNV Likely pathogenic 215997 rs863224451 17:7577114-7577114 17:7673796-7673796
45 TP53 NM_000546.5(TP53):c.517G>T (p.Val173Leu) SNV Likely pathogenic 376668 rs876660754 17:7578413-7578413 17:7675095-7675095
46 NRAS NM_002524.5(NRAS):c.182A>T (p.Gln61Leu) SNV Likely pathogenic 375874 rs11554290 1:115256529-115256529 1:114713908-114713908
47 BRAF NM_001374258.1(BRAF):c.1900G>A (p.Asp634Asn) SNV Likely pathogenic 44813 rs397516896 7:140453155-140453155 7:140753355-140753355
48 TP53 NM_000546.5(TP53):c.395A>G (p.Lys132Arg) SNV Likely pathogenic 376625 rs1057519996 17:7578535-7578535 17:7675217-7675217
49 TP53 NM_000546.5(TP53):c.394A>C (p.Lys132Gln) SNV Likely pathogenic 376628 rs747342068 17:7578536-7578536 17:7675218-7675218
50 GNAS NM_000516.6(GNAS):c.602G>T (p.Arg201Leu) SNV Likely pathogenic 210045 rs121913495 20:57484421-57484421 20:58909366-58909366

Cosmic variations for Adrenal Carcinoma:

9 (show top 50) (show all 118)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM88301868 VHL adrenal gland,adrenal gland,pheochromocytoma,benign c.389T>G p.V130G 3:10146562-10146562 40
2 COSM90654925 VHL adrenal gland,adrenal gland,pheochromocytoma,benign c.260T>C p.V87A 3:10142107-10142107 40
3 COSM88294143 VHL adrenal gland,adrenal gland,pheochromocytoma,benign c.260T>C p.V87A 3:10142107-10142107 40
4 COSM90652830 VHL adrenal gland,adrenal gland,pheochromocytoma,benign c.373G>T p.V125F 3:10149819-10149819 40
5 COSM88293303 VHL adrenal gland,adrenal gland,pheochromocytoma,benign c.475A>G p.K159E 3:10149798-10149798 40
6 COSM88288959 VHL adrenal gland,adrenal gland,pheochromocytoma,benign c.482G>A p.R161Q 3:10149805-10149805 40
7 COSM88296074 VHL adrenal gland,adrenal gland,pheochromocytoma,benign c.250G>C p.V84L 3:10142097-10142097 40
8 COSM88292246 VHL adrenal gland,adrenal gland,pheochromocytoma,benign c.227T>A p.F76Y 3:10142074-10142074 40
9 COSM90652721 VHL adrenal gland,adrenal gland,pheochromocytoma,benign c.368A>G p.Q123R 3:10149814-10149814 40
10 COSM88292324 VHL adrenal gland,adrenal gland,pheochromocytoma,benign c.496G>T p.V166F 3:10149819-10149819 40
11 COSM90657160 VHL adrenal gland,adrenal gland,pheochromocytoma,benign c.250G>C p.V84L 3:10142097-10142097 40
12 COSM88305342 VHL adrenal gland,adrenal gland,pheochromocytoma,benign c.492G>T p.Q164H 3:10149815-10149815 40
13 COSM90653943 VHL adrenal gland,adrenal gland,pheochromocytoma,benign c.352A>G p.K118E 3:10149798-10149798 40
14 COSM90668341 VHL adrenal gland,adrenal gland,pheochromocytoma,benign c.369G>T p.Q123H 3:10149815-10149815 40
15 COSM88292236 VHL adrenal gland,adrenal gland,pheochromocytoma,benign c.491A>G p.Q164R 3:10149814-10149814 40
16 COSM90652730 VHL adrenal gland,adrenal gland,pheochromocytoma,benign c.227T>A p.F76Y 3:10142074-10142074 40
17 COSM90648957 VHL adrenal gland,adrenal gland,pheochromocytoma,benign c.359G>A p.R120Q 3:10149805-10149805 40
18 COSM90664073 VHL adrenal gland,adrenal gland,pheochromocytoma,benign c.341-3225T>G p.? 3:10146562-10146562 40
19 COSM90811579 RET adrenal gland,adrenal gland,pheochromocytoma,benign c.2753T>C p.M918T 10:43121968-43121968 40
20 COSM92347003 RET adrenal gland,adrenal gland,pheochromocytoma,benign c.2753T>C p.M918T 10:43121968-43121968 40
21 COSM142343426 RET adrenal gland,adrenal gland,pheochromocytoma,benign c.1289+3268T>C p.? 10:43114500-43114500 40
22 COSM142343204 RET adrenal gland,adrenal gland,pheochromocytoma,benign c.*102T>C p.? 10:43121968-43121968 40
23 COSM92347226 RET adrenal gland,adrenal gland,pheochromocytoma,benign c.1900T>C p.C634R 10:43114500-43114500 40
24 COSM90811811 RET adrenal gland,adrenal gland,pheochromocytoma,benign c.1900T>C p.C634R 10:43114500-43114500 40
25 COSM93530486 NF1 adrenal gland,adrenal gland,pheochromocytoma,benign c.226G>T p.E76* 17:31159031-31159031 40
26 COSM93656552 NF1 adrenal gland,adrenal gland,pheochromocytoma,benign c.1885G>A p.G629R 17:31225134-31225134 40
27 COSM93692982 NF1 adrenal gland,adrenal gland,pheochromocytoma,benign c.5665G>T p.E1889* 17:31330351-31330351 40
28 COSM93650970 NF1 adrenal gland,adrenal gland,pheochromocytoma,benign c.1466A>G p.Y489C 17:31214524-31214524 40
29 COSM120509060 NF1 adrenal gland,adrenal gland,pheochromocytoma,benign c.1466A>G p.Y489C 17:31214524-31214524 40
30 COSM93535461 NF1 adrenal gland,adrenal gland,pheochromocytoma,benign c.3158C>A p.S1053* 17:31230886-31230886 40
31 COSM109968573 NF1 adrenal gland,adrenal gland,pheochromocytoma,benign c.226G>T p.E76* 17:31159031-31159031 40
32 COSM109960979 NF1 adrenal gland,adrenal gland,pheochromocytoma,benign c.1466A>G p.Y489C 17:31214524-31214524 40
33 COSM93512112 NF1 adrenal gland,adrenal gland,pheochromocytoma,benign c.1885G>A p.G629R 17:31225134-31225134 40
34 COSM93508888 NF1 adrenal gland,adrenal gland,pheochromocytoma,benign c.205-1G>C p.? 17:31159009-31159009 40
35 COSM93509879 NF1 adrenal gland,adrenal gland,pheochromocytoma,benign c.2409+1G>A p.? 17:31227607-31227607 40
36 COSM120509488 NF1 adrenal gland,adrenal gland,pheochromocytoma,benign c.205-1G>C p.? 17:31159009-31159009 40
37 COSM93507010 NF1 adrenal gland,adrenal gland,pheochromocytoma,benign c.7237C>T p.Q2413* 17:31349230-31349230 40
38 COSM93662933 NF1 adrenal gland,adrenal gland,pheochromocytoma,benign c.7582C>T p.Q2528* 17:31352381-31352381 40
39 COSM93654948 NF1 adrenal gland,adrenal gland,pheochromocytoma,benign c.7646C>G p.S2549* 17:31356490-31356490 40
40 COSM93504734 NF1 adrenal gland,adrenal gland,pheochromocytoma,benign c.1721+3A>T p.? 17:31221932-31221932 40
41 COSM93507162 NF1 adrenal gland,adrenal gland,pheochromocytoma,benign c.1466A>G p.Y489C 17:31214524-31214524 40
42 COSM120515658 NF1 adrenal gland,adrenal gland,pheochromocytoma,benign c.226G>T p.E76* 17:31159031-31159031 40
43 COSM93650764 NF1 adrenal gland,adrenal gland,pheochromocytoma,benign c.7300C>T p.Q2434* 17:31349230-31349230 40
44 COSM93517207 NF1 adrenal gland,adrenal gland,pheochromocytoma,benign c.7519C>T p.Q2507* 17:31352381-31352381 40
45 COSM109960306 NF1 adrenal gland,adrenal gland,pheochromocytoma,benign c.1724A>T p.Y575F 17:31221932-31221932 40
46 COSM93652933 NF1 adrenal gland,adrenal gland,pheochromocytoma,benign c.205-1G>C p.? 17:31159009-31159009 40
47 COSM93668028 NF1 adrenal gland,adrenal gland,pheochromocytoma,benign c.1722-1G>A p.? 17:31223443-31223443 40
48 COSM93647950 NF1 adrenal gland,adrenal gland,pheochromocytoma,benign c.1721+3A>T p.? 17:31221932-31221932 40
49 COSM93688082 NF1 adrenal gland,adrenal gland,pheochromocytoma,benign c.6855C>A p.Y2285* 17:31338739-31338739 40
50 COSM109961525 NF1 adrenal gland,adrenal gland,pheochromocytoma,benign c.205-1G>C p.? 17:31159009-31159009 40

Expression for Adrenal Carcinoma

Search GEO for disease gene expression data for Adrenal Carcinoma.

Pathways for Adrenal Carcinoma

Pathways related to Adrenal Carcinoma according to GeneCards Suite gene sharing:

(show all 49)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.04 TP53 PIK3CA NRAS GNAS CTNNB1 CCND1
2
Show member pathways
13.02 POMC NRAS GNAS CTNNB1 CRH BRAF
3
Show member pathways
12.96 TP53 PIK3CA NRAS IGF2 GNAS CTNNB1
4
Show member pathways
12.88 TP53 PIK3CA NRAS GNAS CTNNB1 CCND1
5
Show member pathways
12.85 TP53 PIK3CA NRAS CTNNB1 CCND1 BRAF
6
Show member pathways
12.71 PIK3CA NRAS IGF2 GNAS CTNNB1 BRAF
7
Show member pathways
12.7 TP53 PIK3CA NRAS CTNNB1 BRAF
8 12.65 TP53 PIK3CA NRAS IGF2 GNAS CTNNB1
9
Show member pathways
12.64 TP53 PIK3CA NRAS GNAS CCND1 BRAF
10
Show member pathways
12.64 TP53 PIK3CA NRAS IGF2 CTNNB1 CCND1
11
Show member pathways
12.62 PIK3CA NRAS GNAS CTNNB1 CCND1
12
Show member pathways
12.6 TP53 PIK3CA NRAS CCND1 BRAF
13 12.52 TP53 PIK3CA NRAS MIR483 CCND1
14
Show member pathways
12.39 TP53 PIK3CA IGF2 CCND1
15
Show member pathways
12.39 PIK3CA NRAS IGF2 CTNNB1 BRAF
16 12.33 TP53 PIK3CA NRAS CCND1
17 12.32 POMC PIK3CA GNAS BRAF
18
Show member pathways
12.32 PIK3CA NRAS CTNNB1 BRAF
19
Show member pathways
12.3 TP53 PIK3CA CTNNB1 CCND1
20 12.29 TP53 PIK3CA NRAS CCND1
21
Show member pathways
12.22 TP53 PIK3CA NRAS CCND1 BRAF
22
Show member pathways
12.16 TP53 PIK3CA NRAS BRAF
23 12.14 TP53 GNAS CTNNB1 CCND1 BRAF
24 12.09 TP53 PIK3CA NRAS CCND1 CCNB1
25
Show member pathways
12.09 POMC NRAS GNAS CYP21A2 CYP17A1 CYP11B2
26 12.06 TP53 GRN CTNNB1 CCND1 BRAF
27
Show member pathways
12.02 PIK3CA GNAS CTNNB1 BRAF
28 12.01 TP53 PIK3CA NRAS IGF2 CTNNB1 CCND1
29
Show member pathways
11.99 PIK3CA NRAS CCND1 CCNB1 BRAF
30 11.88 TP53 PIK3CA NRAS CTNNB1 CCND1
31 11.83 TP53 PIK3CA NRAS CTNNB1 CCND1
32
Show member pathways
11.8 PIK3CA NRAS BRAF
33 11.78 TP53 NRAS IGF2 CTNNB1 CCND1 BRAF
34 11.77 NRAS CCND1 CCNB1
35
Show member pathways
11.77 POMC CYP21A2 CYP17A1 CYP11B2
36 11.73 PIK3CA NRAS BRAF
37 11.71 TP53 PIK3CA NRAS
38 11.71 TP53 NRAS CCND1 BRAF
39 11.69 PIK3CA GNAS BRAF
40
Show member pathways
11.68 CYP21A2 CYP17A1 CYP11B2
41 11.59 NRAS GNAS CRH BRAF
42 11.57 PIK3CA CCND1 BRAF
43 11.57 TP53 PIK3CA CCND1
44 11.4 POMC GNAS CYP21A2 CTNNB1 CRH BRAF
45 11.31 PIK3CA CTNNB1 CCND1
46 11.29 TP53 CCND1 CCNB1
47 11.14 PIK3CA GNAS BRAF
48
Show member pathways
11.08 CYP21A2 CYP17A1 CYP11B2
49 10.51 POMC CRH

GO Terms for Adrenal Carcinoma

Biological processes related to Adrenal Carcinoma according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 in utero embryonic development GO:0001701 9.76 TP53 IGF2 CTNNB1 CCNB1
2 multicellular organism growth GO:0035264 9.67 TP53 H3-3A GNAS
3 steroid biosynthetic process GO:0006694 9.61 CYP21A2 CYP17A1 CYP11B2
4 positive regulation of neuron apoptotic process GO:0043525 9.58 TP53 GRN CTNNB1
5 positive regulation of axon regeneration GO:0048680 9.51 GRN BRAF
6 mitotic G1 DNA damage checkpoint GO:0031571 9.48 TP53 CCND1
7 steroid metabolic process GO:0008202 9.46 CYP21A2 CYP17A1 CYP11B2 CRH
8 response to drug GO:0042493 9.43 TP53 GNAS CTNNB1 CRH CCND1 CCNB1
9 hair follicle placode formation GO:0060789 9.37 GNAS CTNNB1
10 insulin receptor signaling pathway via phosphatidylinositol 3-kinase GO:0038028 9.32 PIK3CA IGF2
11 mineralocorticoid biosynthetic process GO:0006705 9.26 CYP21A2 CYP11B2
12 glucocorticoid biosynthetic process GO:0006704 8.8 CYP21A2 CYP17A1 CYP11B2

Molecular functions related to Adrenal Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen GO:0016705 9.13 CYP21A2 CYP17A1 CYP11B2
2 corticotropin-releasing hormone receptor 1 binding GO:0051430 8.62 GNAS CRH

Sources for Adrenal Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....